Trial Profile
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca; Sanofi Genzyme
- 22 Sep 2023 Planned End Date changed from 29 Dec 2023 to 28 Jun 2024.
- 03 Oct 2022 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
- 20 Oct 2021 Planned End Date changed from 30 Dec 2020 to 31 Dec 2022.